Sign inJoin waitlistJoin the waitlist

MO

Michael Offin

Co-Director, Mesothelioma Program · New York Presbyterian Hospital

Credentials: · · · · · ·

History

Mesothelioma Program · New York Presbyterian Hospital
Present

Medical Oncology
Memorial Sloan Kettering Cancer Center
2016–2019
Hospital of the University of Pennsylvania
2013–2016
Rutgers New Jersey Med Sch
2009–2013

Research

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Journal of Clinical Oncology · 2018 · 495 citations
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
Clinical Cancer Research · 2019 · 408 citations
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes
Journal of Thoracic Oncology · 2019 · First of 17 authors · 374 citations

Charles Rudin
34 papers
ML
Marc Ladanyi
34 papers
AD
Alexander Drilon
30 papers
GR
Gregory Riely
28 papers
MK
Mark Kris
28 papers
BL
Bob Li
26 papers
Marjorie Zauderer
26 papers
AR
Andreas Rimner
25 papers
MA
Maria Arcila
23 papers
HY
Helena Yu
21 papers
Jennifer Sauter
21 papers
NR
Natasha Rekhtman
21 papers

Grants

Intraperitoneal CAR T-Cell Therapy for Peritoneal Mesothelioma
Food and Drug Administration · R01
PI · $650K · Sloan-Kettering Inst Can Research
2026–2030

Clinical trials

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Principal investigator · Recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
2026–2029
A Study of Sacituzumab Govitecan in People With Mesothelioma
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2024–2029
A Study of Pembrolizumab and Cryoablation in People With Mesothelioma
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2021–2023
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
Principal investigator · Active not recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
2019–2027